Biofidelity raises $24 million in financing to accelerate commercialization and expand product pipeline.
Biofidelity raises $24 million in financing to accelerate commercialization and expand product pipeline.
04/03/24, 12:59 PM
Location
cambridgeMoney raised
$24 million
Industry
health care
Investors
Longwall Ventures, Blue Yard Capital, Octopus Ventures, Agilent Technologies
Biofidelity successfully completed a financing round totalling $24 million, which will accelerate the growth of the Company, including commercial and clinical expansion, and enable the establishment of a dedicated manufacturing facility in the United Kingdom.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. We have launched our first product, ASPYRE-Lung, in the US and we have an extensive pipeline of novel products.
Biofidelity has developed a novel molecular biology technology which enables genomic analysis for cancer diagnosis to be carried out locally, quickly and far more cost-effectively.